To treat inflammatory diseases, including rheumatoid arthritis and Crohn’s disease, biopharmaceutical drugs targeting TNF, IL-1, and IL-6 provided satisfactory outcomes [34,35]. This evidence concerns the gene IL6 and rheumatoid arthritis.